You are on page 1of 2

FACT SHEET April / May 2011

Since 2006, Adamis Pharmaceuticals Corporation (OTCBB: ADMP) has established

themselves with an enviable product pipeline within the biopharmaceutical industry.
OTCQB: ADMP By combining specialty pharmaceuticals and biotechnology to provide innovative
medicines, Adamis is uniquely positioned with products in 3 major therapeutic areas,
including: Allergy/Respiratory (Asthma/COPD), Oncology (Cancer) and
Share Information Immunology and Infectious Diseases (Viruses).

OTCQB: ADMP Recent Results Headline News

(a fully-reporting company)
• Adamis Reports APC-300 Kills Human Pancreatic Cancer Cells 03/24/11
Recent price………………. $0.20
Outstanding shrs……. 81.6 million • Adamis Files IND for Product Candidate to Treat Prostate Cancer 03/09/11
Public float………… 47.2 million
• Adamis Announces Phase 3 Meets Primary Endpoint 12/07/10
52-week range……. $0.36 - $0.15
Avg. volume (90-days)…. 58,000 • Adamis & Beximco Pharma Announce Manufacturing Agreement 12/01/10

Market cap…………… $15 million • Adamis Completes $10 million Stock Purchase [Funding] Agreement 11/11/10
Fiscal year end……... March 31st
• Adamis Completes Acquisition of Prostate Drug Candidates 10/19/10

Executive Mgmt.
has two (2) wholly-owned subsidiaries:
Dennis J. Carlo, Ph.D.
President and CEO Adamis Laboratories, Inc. (specialty pharmaceuticals), which has
a line of prescription products in the anti-inflammatory, allergy and
Robert O. Hopkins, CFO respiratory field. Adamis Labs’ has just begun pre-launch activities for additional products.

David J. Marguglio, Senior VP Adamis Therapeutics, Inc. (biotechnology), which is primarily focused on the development
of patented, proprietary technologies for the potential treatment of human prostate cancer.
Thomas Moll, Ph.D.
Vice President /Research ♦ ♦ BLOCKBUSTER POTENTIAL ♦ ♦
Adamis Therapeutics is developing first-in-class products with “blockbuster” potential.
Karen K. Daniels
During the 4th quarter of 2010, the Company obtained exclusive worldwide rights to
Vice President /Operations
three new compounds for the treatment of prostate cancer (see 10/19/10 news below).
Richard L. Aloi SAN DIEGO -- Oct. 19, 2010 -- Adamis Pharmaceuticals Corporation (OTCBB: ADMP),
Adamis Laboratories, President announced the acquisition from Colby Pharmaceuticals of the remaining exclusive license
agreements relating to the remaining 2 of 3 drug product candidates for the treatment of
prostate cancer (PCa). Adamis has now acquired the exclusive licenses covering
three (3) molecule compounds, named APC-100, APC-200 and APC 300.

Over $18 million in U.S. Gov’t funds have been awarded for the development of APC-100,
APC-200 and APC-300 by: the Congressionally Directed Medical Research Program, the
Prostate Cancer Research Program (PCRP), and the National Cancer Institute (NCI).
APC-100 has also been privately funded by Michael Milken's Prostate Cancer Foundation.
Adamis Pharmaceuticals Corp.
2658 Del Mar Heights Road
Del Mar, California 92014 In 2006 and 2007, both the APC-100 and APC-200 compounds won the prestigious
National Cancer Institute Rapid Award, which is given to drugs the NCI considers to be
Tel. # 858.401.3984 the most promising new drugs for the treatment of cancer.
Adamis Pharmaceuticals Corporation has strong patent claims in the United States
and in certain foreign markets with other foreign applications in progress.


Company Fact Sheet...
produced by Heritage First Capital Page 2 ▼
& Equity Research Group
Copyright © 2011 Heritage First Capital / / Tel. 407.444.5959 / Greater Orlando
Potential Cancer Vaccine Blockbuster
Adamis Pharmaceuticals Corp.’s Prostate Cancer Vaccine:
Adamis Pharmaceuticals is developing a novel cell-based cancer vaccine, TeloB-VAX. OTCQB: ADMP
Adamis’ therapeutic cancer vaccine is conceptually distinct from the only FDA approved cell-based cancer vaccine, Provenge®
(Dendeon Corp./Nasdaq: DNDN), which is said to use the patient’s own dendritic cells (though it’s not definitively proven).

TeloB-VAX utilizes the patient’s own B cells as antigen producing and antigen presenting cells. (B cells represent approx. 12% of
circulating blood cells).

Adamis believes its technology offers major advantages over the FDA approved Provenge® vaccine. These advantages, include:

1) prolonged antigen presentation by B cells (5 days) as compared to the short presentation time by dendritic cells (12 hours),

2) a unique patented platform technology using a universal cancer antigen that is increased in approximately 85% of all tumors,

3) immunity after a single injection, 4) no need for complicated culture procedures, 5) significantly fewer steps, 6) lower cost and

7) technology built on strong stringent scientific rationale. NOTE: TeloB-VAX may very well be called a “universal cancer vaccine”
that could induce immunity against multiple cancer types as well as targeting the specific cancer stem cell.

Currently Adamis is planning a Phase 2 study in castrate resistant prostate cancer (CRPC) patients. The study will be conducted at the
University of Wisconsin Carbone Cancer Center and at UCSD. Adamis is expected to submit an IND application to the FDA within weeks.


Adamis Laboratories and their specialty pharmaceuticals are expected to generate significant revenues first. With several
new product candidates in the Allergy and Respiratory categories in the advanced stages of Adamis Labs’ development pipeline, the
Company is projecting profitability as early as the first quarter of 2012. These near market ready products include the Epinephrine
Pre-Filled Syringe, and HFA aerosolized Inhaled Nasal Steroid, and two respiratory pMDI product candidates for asthma and COPD.

Please see for in-depth medical product descriptions, key attributes and market potential data.
The natural brevity of this fact sheet has excluded other significant corporate assets, including wholly-owned subsidiary, Adamis
Laboratories’ intellectual property rights for a microbicide contraception gel product candidate named Savvy® (C31G).


Disclaimer: Heritage First Capital & Equity Research Group (HFC), based upon information supplied by sources believed
to be reliable, herein prepared all material. This opinion contains forward-looking statements that involve risks and
uncertainties. A company's actual results could differ materially from those described in any forward-looking statements
discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation
of an offer to buy or sell securities. HFC is not a licensed broker, broker dealer, market marker, investment banker,
financial advisor, analyst or underwriter. Please note that HFC has been compensated in cash directly by the Company.

Copyright © 2011 Heritage First Capital / / Tel. 407.444.5959 / Greater Orlando